Related Experiment Video
Updated: May 23, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Brentuximab vedotin in systemic T-cell lymphoma
1Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. yoki@mdanderson.org
Expert Opinion on Biological Therapy
|March 21, 2012
Summary
Brentuximab vedotin is effective for treating relapsed Hodgkin
Area of Science:
- Oncology
- Pharmacology
Background:
- Brentuximab vedotin is an antibody-drug conjugate targeting CD30.
- It is approved for relapsed/refractory Hodgkin's lymphoma (HL) and anaplastic large cell lymphoma (ALCL).
- Its efficacy in other CD30(+) lymphomas is under investigation.
Purpose of the Study:
- To review current treatments for systemic peripheral T-cell lymphomas (PTCL).
- To examine brentuximab vedotin's role in relapsed/refractory ALCL.
- To review ongoing trials of brentuximab vedotin in relapsed PTCL and combination therapies.
Main Methods:
- Literature review of treatment options for PTCL.
- Review of brentuximab vedotin's efficacy in ALCL.
- Analysis of ongoing clinical trials for PTCL and combination therapies.
Main Results:
- Brentuximab vedotin is established for relapsed/refractory HL and ALCL.
- Further data on its use in other CD30(+) lymphomas is anticipated.
- Combination regimens, including frontline use, are under investigation.
Conclusions:
- Brentuximab vedotin is a key treatment for specific lymphomas.
- Ongoing research will define its broader applications and combination strategies.
- Future studies will clarify its role in frontline therapy and other CD30(+) malignancies.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...